Biocon Limited

Biocon Limited (BIOCON) is a mid-cap Healthcare company valued at ₹57,039 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Biocon Limited last traded at ₹349.2, modestly down 0.80% on the day.

Recent developments

On 2026-10-14, the company secured a global patent settlement with Genentech for the breast cancer drug Pebrilzo, resolving all pending disputes across multiple jurisdictions. The same day, the company cleared patent hurdles for Pebrilzo, paving the way for commercialization. On 2026-09-25, the company received UK MHRA approval for a new drug product fill-finish unit in Malaysia, supporting the production of Semglee insulin and other biologics.

Financial performance

The company's business has grown, with annual revenue rising 10.9% year-over-year. However, net profit fell sharply by -74.2% year-over-year, and the net profit margin dropped 7.2 percentage points to 2.2%. The latest quarter saw revenue rise 10.0% compared to the same quarter a year earlier, while net profit surged 53.4%.

Valuation multiples

The stock trades at 26.9 times earnings, a discount to the Healthcare median of 32.0, 1.84 times book value. It yields 0.1%.

Things to watch

The company's net profit margin has fallen significantly to 2.2%, down 7.2 percentage points from the prior year. The latest quarter's net profit was 53.4% higher than the same quarter a year earlier, but annual net profit fell by -74.2% year-over-year. The stock is 21.9% below its 52-week high.

Where it stands

The company's revenue has grown steadily, but net profit has declined sharply, with the net profit margin falling to 2.2%. The latest quarter saw a significant rise in net profit, but annual net profit fell by -74.2%. The stock is 21.9% below its 52-week high.

Summarised by DocStoX's model on 2026-10-17 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.